RE:RE:RE:Could The Ellipses Leak Force a Plan B?Poof, you gotta be kidding us. That's not the question. The question is whether Rathjen and the BoD have held deals back that would have saved Bioasis from this sellout.
I didn't leak the Ellioses deal. Rathjen did. It looks to me like she had a deal and was going to use it to pitch Bioasis to Midatech, all under the the watchful and excited gaze of LT and The Placee.
The trouble is, xB3-001 doesn't need Midatech. I doubt that Midatech/Biodexa can do anything with xB3-001 without further dilution. Midatech/Biodexa wilk likely do a deal like Bioasis could have done where a partner for xB3-001 or a buyer of xB3-001 could do the clinical work and foot the bill for it.
The timing of the leak, Rathjen's presence in North America and the first meeting between Bioasis and Midatech together create a strong suspicion that Bioasis had a deal but was holding it back to get this lopsided sellout done.
If that is the case, how much more business has been postponed until LT and The Placee get control of Biodexa?
And if business has been postponed, which the entire BoD may or may not have known about, how much has been postponed until LT and The Placee get control of Biodexa?
Have Rathjen and Saltarelli delayed business deals for their own benefit at the expense of Bioasis shareholders? I contend that there is enough evidence of that to warrant some questions by regulators. Have deals been delayed, postponed, waved off or discouraged in favour of Midatech/Biodexa, Rathjen, Saltarelli, and LT and The Placee?
It's all very simple, poof. It has nothing at all to do with what Midatech/Biodexa can or can't do. In the end they also will be under the control of LT and The Placee. Are Rathjen and Saltarelli, once on the BoD of Biodexa, going to be representing the interests of LT and The Placee? So far, it looks like their efforts are benefitting LT and The Placee and themselves far more than they are for anybody else.
Call in the stock fuzz!
jd